MERCK & CO., INC.
Last · NYSE$147.35+5.37 (+3.78%)close · yahoo · 6h ago
Market cap$363.54B2.47B sh
P/E · TTM117fwd 15.8 · eps 1.26
Beta0.22vs S&P 500
Div yield2.34%annual · TTM
52w range
$82.01$156.92
Volume8.0Msession
| Revenue | $66.6B |
|---|---|
| Operating income | $-4.2B |
| Net income | $3.2B |
| Free cash flow | $16.1B |
| Operating margin | -6.3% |
| Net margin | 4.8% |
| Return on equity | 7.6% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-24
- Keytruda Concentration
- Patent Cliffs
- Gardasil China
- Januvia Generic Entry
- Pipeline Execution
- Product Liability
- Debt Increase
Red flags
- Keytruda represented 49% of total 2025 sales, creating substantial single-product concentration risk.
- Sales were nearly flat in 2025 at $65.0 billion, up only 1%, while the company faces several large product losses in 2026 and expects Keytruda pressure from biosimilars beginning in late 2028.
- Merck had approximately 610 pending Dr. Scholl’s foot-powder product-liability cases and approximately 135 pending Gardasil/Gardasil 9 cases as of December 31, 2025.
- Merck states it has no insurance for most product liabilities because the cost of available coverage outweighs the expected benefits.
- Long-term debt rose to $46.75 billion at year-end 2025 from $34.46 billion, alongside the $8.0 billion debt issuance in December 2025.
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$2.11
Est. revenue
17.3B
Earnings transcripts
Press & signals
- Satelight
Ebola death toll rises to 930, as outbreak spreads at record pace